---
title: "Purple Biotech Ltd. Files Prospectus for $6 Million Public Offering with Potential for Additional $12 Million from Warrants"
description: "Purple Biotech Ltd. has filed a prospectus for a public offering of 5,999,999 American Depositary Shares (ADSs) at $1.00 each, aiming to raise approximately $6 million. The offering includes short-ter"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256171916.md"
published_at: "2025-09-05T16:44:04.000Z"
---

# Purple Biotech Ltd. Files Prospectus for $6 Million Public Offering with Potential for Additional $12 Million from Warrants

> Purple Biotech Ltd. has filed a prospectus for a public offering of 5,999,999 American Depositary Shares (ADSs) at $1.00 each, aiming to raise approximately $6 million. The offering includes short-term warrants for an additional 11,999,998 ADSs, potentially increasing proceeds by $12 million if fully exercised. The funds will support the development of oncology therapies and general corporate purposes, facilitated by H.C. Wainwright & Co. as the exclusive placement agent.

Purple Biotech Ltd., a clinical-stage company focused on developing therapies to combat tumor immune evasion and drug resistance, has announced the pricing of a public offering involving 5,999,999 American Depositary Shares (ADSs) and short-term warrants to purchase up to 11,999,998 ADSs. Each ADS represents 200 ordinary shares, with a combined public offering price set at $1.00 per share. These short-term warrants are exercisable immediately and will expire 24 months from issuance. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, is pursuant to a registration statement on Form F-1 filed with the SEC. The gross proceeds are estimated to be approximately $6 million, with potential additional proceeds of $12 million if the short-term warrants are fully exercised. The funds are intended for the development of oncology therapeutic candidates and general corporate purposes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Purple Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-084858), on September 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PPBT.US - Purple Biotech](https://longbridge.com/en/quote/PPBT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Purple Biotech Im1240 On Track Towards First-In-Human Clinical Trials | Purple Biotech Ltd :PURPLE BIOTECH LTD - IM1240 ON TRACK TOWARDS FIRST-IN-HUMAN CLINICAL TRIALS, WITH REGULATORY SUBMISS | [Link](https://longbridge.com/en/news/271798240.md) |
| Purple Biotech to Present New Preclinical Data on CAPTN-3 Tri-Specific Antibody Platform at ESMO-IO 2025 | Purple Biotech Ltd. will present new preclinical data on its CAPTN-3 tri-specific antibody platform at the ESMO-IO 2025  | [Link](https://longbridge.com/en/news/268598629.md) |
| Thomas Charles Heineman Purchases 12,132 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock | Oncolytics Biotech Inc. insider Thomas Charles Heineman purchased 12,132 shares at $0.83 each, totaling $10,069.56, incr | [Link](https://longbridge.com/en/news/275978822.md) |
| Coya Therapeutics Stock Poised To Appreciate As Company Advances Superior ALS Therapy | Coya Therapeutics (COYA), a clinical-stage biotech firm, is advancing its lead candidate, COYA 302, for ALS and FTD, uti | [Link](https://longbridge.com/en/news/275894413.md) |
| Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? | Neumora Therapeutics presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, aiming to enhance its | [Link](https://longbridge.com/en/news/275638594.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.